We are live on
!
Find out more
PAP
Persistent Asset Partners Portfolio holdings
AUM
$268M
1-Year Est. Return
158.98%
This Fund
S&P 500
This Quarter
Est. Return
+2.11%
1 Year Est. Return
+158.98%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$119M
AUM Growth
-$1.36M
(-1.1%)
Cap. Flow
+$6.26M
Cap. Flow
% of AUM
5.25%
Top 10 Holdings %
Top 10 Hldgs %
39.35%
Holding
221
New
78
Increased
37
Reduced
38
Closed
48
Top Buys
| 1 |
iShares Bitcoin Trust
IBIT
|
+$7.97M |
| 2 |
Centene
CNC
|
+$7.51M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
+$4.8M |
| 4 |
Jazz Pharmaceuticals
JAZZ
|
+$2.61M |
| 5 |
Eli Lilly
LLY
|
+$2.51M |
Top Sells
| 1 |
Humana
HUM
|
+$9.46M |
| 2 |
DaVita
DVA
|
+$5.09M |
| 3 |
WBA
Walgreens Boots Alliance
WBA
|
+$3.51M |
| 4 |
Cardinal Health
CAH
|
+$2.43M |
| 5 |
DFS
Discover Financial Services
DFS
|
+$1.87M |
Sector Composition
| 1 | Healthcare | 60.53% |
| 2 | Financials | 20.86% |
| 3 | Materials | 3.73% |
| 4 | Energy | 1.78% |
| 5 | Industrials | 0.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Cytokinetics
CYTK
$10.9B
| $184K | 0.15% |
+4,576
| New | +$210K |
|
|
CLYM
102
Climb Bio
CLYM
$727M
| $178K | 0.15% |
145,760
| – | – |
|
103
Replimune Group
REPL
$859M
| $167K | 0.14% |
17,143
-11,960
| -41% | -$148K |
|
104
Clover Health Investments
CLOV
$2.43B
| $163K | 0.14% |
+45,276
| New | +$182K |
|
|
105
CALL
Jazz Pharmaceuticals
JAZZ
$15.5B
| $158K | 0.13% |
+163
| New | +$21.3K |
|
|
RVPH
106
DELISTED
REVIVA PHARMA HLDGS INC
RVPH
| $153K | 0.13% |
8,016
-43
| -0.5% | -$1.35K |
|
107
PUT
Moderna
MRNA
$24.5B
| $152K | 0.13% |
230
-38
| -14% | -$1.35K |
|
108
PUT
Amgen
AMGN
$198B
| $152K | 0.13% |
+120
| New | +$35.4K |
|
|
MREO
109
CALL
Mereo BioPharma
MREO
$49.5M
| $147K | 0.12% |
+1,186
| New | +$3.35K |
|
110
loanDepot
LDI
$591M
| $145K | 0.12% |
+122,159
| New | +$198K |
|
|
SLSR
111
Solaris Resources
SLSR
$1.18B
| $141K | 0.12% |
41,812
| – | – |
|
112
Alector
ALEC
$167M
| $129K | 0.11% |
+104,927
| New | +$171K |
|
113
PUT
Biomea Fusion
BMEA
$92.5M
| $126K | 0.11% |
406
+191
| +89% | +$651 |
|
|
NVO
114
PUT
Novo Nordisk
NVO
$223B
| $122K | 0.1% |
287
-203
| -41% | -$16.8K |
|
|
115
PUT
Regeneron Pharmaceuticals
REGN
$70.9B
| $112K | 0.09% |
+46
| New | +$31.6K |
|
116
uniQure
QURE
$2.77B
| $88.9K | 0.07% |
+8,386
| New | +$118K |
|
117
Olema Pharmaceuticals
OLMA
$1B
| $86.4K | 0.07% |
+22,988
| New | +$116K |
|
|
AVR
118
Anteris Technologies
AVR
$823M
| $84.9K | 0.07% |
+23,317
| New | +$150K |
|
119
CALL
Gossamer Bio
GOSS
$83.2M
| $80K | 0.07% |
1,929
+1,151
| +148% | +$1.33K |
|
120
CALL
Recursion Pharmaceuticals
RXRX
$1.56B
| $79.9K | 0.07% |
1,606
+700
| +77% | +$5.1K |
|
121
CALL
Edgewise Therapeutics
EWTX
$4.28B
| $75K | 0.06% |
226
+126
| +126% | +$3.31K |
|
122
PUT
Cogent Biosciences
COGT
$6.68B
| $72K | 0.06% |
+479
| New | +$3.76K |
|
|
123
CALL
Eli Lilly
LLY
$1.05T
| $70.2K | 0.06% |
+23
| New | +$19.1K |
|
124
CALL
Ocular Therapeutix
OCUL
$1.96B
| $69.9K | 0.06% |
313
| – | – |
|
|
125
Gossamer Bio
GOSS
$83.2M
| $68.2K | 0.06% |
61,984
-3,910
| -6% | -$4.52K |
|
Similar funds
VC
AL
FC
NF
PF
UI
SSWM
AC
Persistent Asset Partners's Q1 2025 Portfolio in Review
As of Q1 2025, Persistent Asset Partners held 221 positions worth $119M, down 1.1% from $121M the previous quarter. Its ten largest holdings account for 39% of the portfolio.
Persistent Asset Partners deployed $6.26M of net new capital in Q1 2025, opening 78 new positions and adding to 37 existing holdings. Its largest new stake was iShares Bitcoin Trust: 150,623 shares worth $7.05M.
By sector, the portfolio is most concentrated in Healthcare at 61% of assets, down from 68% a quarter earlier, followed by Financials and Materials.
On the sell side, the largest reduction was Humana, an estimated $9.46M trimmed.
- Persistent Asset Partners's largest Q1 2025 buy was iShares Bitcoin Trust: 150,623 shares worth $7.05M.
- Persistent Asset Partners added most to Centene in Q1 2025, an estimated $7.51M increase.
- Persistent Asset Partners's biggest Q1 2025 reduction was Humana, cutting an estimated $9.46M.
- Persistent Asset Partners fully exited Walgreens Boots Alliance in Q1 2025, selling an estimated $3.51M.
- Persistent Asset Partners's ten largest holdings make up 39% of its $119M portfolio in Q1 2025.
- Persistent Asset Partners opened 78 new positions and closed 48 in Q1 2025.
- Persistent Asset Partners's portfolio value fell 1.1% quarter-over-quarter to $119M.
Based on Persistent Asset Partners's 13F filing for Q1 2025, filed 13 May 2025.